Investor Meet Company - Audio Archive

Investor Meet Company

An audio archive of all investor presentations from UK listed companies hosted on Investor Meet Company.

Investor Meet Company - Audio Archive

SEED INNOVATIONS LIMITED - AGM Proceedings 2026

Episode discussion: SEED Innovations Limited AGM 2026: Ordinary and Special Resolutions Passed Amidst IT Outage

Speakers’ claims: Speaker 0 opened the recording with a disclaimer and apologized for technical interruptions. Speaker 1 welcomed attendees to the Seed Innovations Limited AGM 2026, noting that the scheduled investor update was cancelled due to a global Microsoft outage. Speaker 3, Luke Kienz, chaired the meeting and presented ordinary resolutions, which included receiving the annual reports for the year ended 31 March 2026, reappointing Grant Thornton as auditor, and electing directors Jim Mellon, Dedham Eke, Sir James Butnell, and Kienz himself. Special resolutions were also passed to empower directors to issue equity without pre-emption rights and to approve the company's migration from Jersey to the Isle of Man, pending regulatory consent. Speaker 1 closed the session after thanking attendees.

AGM ProceedingsCorporate GovernanceInvestment Management
6 min0 assets10 claims to verify
Investor Meet Company - Audio Archive

4BASEBIO PLC - Investor Presentation

Episode discussion: 4BASEBIO outlines synthetic DNA platform, Phase 2 partnership, and path to cash flow positivity

Speakers’ claims: CEO Amy Walker and CFO Richard Bungie present 4BASEBIO's enzymatically produced synthetic DNA technology, positioning it as a faster, purer alternative to plasmid DNA for cell and gene therapy manufacturing. The company highlights a recent direct Phase 2 clinical supply agreement and partnerships with Genizon and TriLink Technologies. Management claims the technology supports over 120 customers and four INDs/CTAs, with a pipeline value exceeding £60 million. They project that achieving £21-22 million in annual revenue with 75% gross margins would make the business cash flow positive, citing upfront payments as a liquidity driver. The presentation also addresses H1 2026 overheads, attributing them to one-off GMP certification costs, and outlines a target steady-state cost base of £15-16 million.

BiotechnologyGene TherapySynthetic Biology
40 min0 assets20 claims to verify